Clinical prognostic factors in pediatric adrenocortical tumors: A meta-analysis.
adrenocortical carcinoma
adrenocortical tumors
children
meta-analysis
prognosis study
prognostic factors
systematic review
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
01
10
2020
revised:
27
10
2020
accepted:
14
11
2020
pubmed:
12
12
2020
medline:
3
8
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
Pediatric adrenocortical tumors (ACT) are rare and sometimes aggressive malignancies, but there is no consensus on the outcome predictors in children. A systematic search of MEDLINE, SCOPUS, Web of Science, and the Cochrane Library for studies from 1994 to 2020 about pediatric ACT was performed. In 42 studies, 1006 patients, aged 0-18 years, were included. The meta-analyses resulted in the following predictors of better outcome: age <4 years (P < .00001), nonsecreting tumors (P = .004), complete surgical resection (P < .00001), tumor volume (P < .0001), tumor weight (P < .00001), tumor maximum diameter (P = .0009), and Stage I disease (P < .00001). Moreover, patients affected by Cushing syndrome showed a worse outcome (P < .0001). International prospective studies should be implemented to standardize clinical prognostic factors evaluation, together with pathological scores, in the stratification of pediatric ACT.
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28836Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Ribeiro RC, Pinto EM, Zambetti GP, Rodriguez-Galindo C. The International Pediatric Adrenocortical Tumor Registry initiative: contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Mol Cell Endocrinol. 2012;351:37-43.
Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol. 2004;22:838-845.
Dehner LP. Pediatric adrenocortical neoplasms: on the road to some clarity. Am J Surg Pathol. 2003;27(7):1005-1007.
Dehner LP, Hill DA. Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors. Pediatr Dev Pathol. 2009;12:284-291.
Dall'Igna P, Virgone C, De Salvo GL, et al. Adrenocortical tumors in Italian children: analysis of clinical characteristics and P53 status. Data from the national registries. J Pediatr Surg. 2014;49:1367-1371.
Wieneke JA, Thompson LD, Heffess CS. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol. 2003;27:867-881.
Picard C, Orbach D, Carton M, et al. Revisiting the role of the pathological grading in pediatric adrenal cortical tumors: results from a national cohort study with pathological review. Mod Pathol. 2019;32:546-559.
Cecchetto G, Ganarin A, Bien E, et al. Outcome and prognostic factors in high-risk childhood adrenocortical carcinomas: a report from the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT). Pediatr Blood Cancer. 2017;64(6):e26368.
Gulack BC, Rialon KL, Englum BR, et al. Factors associated with survival in pediatric adrenocortical carcinoma: an analysis of the National Cancer Data Base (NCDB). J Pediatr Surg. 2016;51:172-177.
Henderson LK, Craig JC, Willis NS, Tovey D, Webster AC. How to write a Cochrane systematic review. Nephrology (Carlton). 2010;15(6):617-624.
NHS Centre for Reviews and Dissemination. Systematic Reviews. CRD's Guidance for Undertaking Reviews in Health Care. York, UK: Centre for Reviews and Dissemination, University of York; 2009
Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149(12):889-897.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality if Nonrandomized Studies in Meta-Analyses. Ottawa, Canada: Ottawa Health Research Institute; 1999. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed June 28, 2020.
Sandrini R, Ribeiro RC, DeLacerda L. Childhood adrenocortical tumors. J Clin Endocrinol Metab. 1997;82:2027-2031.
Barbosa AS, Giacaglia LR, Martin RM, Mendonca BB, Lin CJ. Assessment of the role of transcript for GATA-4 as a marker of unfavorable outcome in human adrenocortical neoplasms. BMC Endocr Disord. 2004;4(1):3.
Bergadá I, Venara M, Maglio S, et al. Functional adrenal cortical tumors in pediatric patients: a clinicopathologic and immunohistochemical study of a long term follow-up series. Cancer. 1996;77(4):771-777.
Silva Borges K, Antunes Moreno D. Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): overexpression of Aurora kinases A and B is associated with a poor prognosis. Pediatr Blood Cancer. 2013;60:1809-1816.
Chatterjee G, DasGupta S, Mukherjee G, et al. Usefulness of Wieneke criteria in assessing morphologic characteristics of adrenocortical tumors in children. Pediatr Surg Int. 2015;31(6):563-571.
Custodio G, Parise GA, Filho NK, et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J Clin Oncol. 2012;31(20):2619-2626.
Damiani D, Della Manna T, Aquino LGW, et al. Proliferating cell nuclear antigen immunoreaction in adrenal tumors. Tumori. 1995;81:273-277.
Das S, Sengupta M, Islam N, et al. Weineke criteria, Ki-67 index and p53 status to study pediatric adrenocortical tumors: is there a correlation? J Pediatr Surg. 2016;51(11):1795-1800.
Federici S, Galli G, Ceccarelli PL, et al. Adrenocortical tumors in children: a report of 12 cases. Eur J Pediatr Surg. 1994;4(1):21-25.
Figueiredo BC, Cavalli LR, Pianovski MA, et al. Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. J Clin Endocrinol Metab. 2005;90(2):615-619.
Fragoso MC, Almeida MQ, Mazzuco TL, et al. Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. Eur J Endocrinol. 2012;166(1):61-67.
NazliGönç E, Özön ZA, Çakir MD, Alikasifoglu A, Kandemir N. Need for comprehensive hormonal workup in the management of adrenocortical tumors in children. J Clin Res Pediatr Endocrinol. 2014;6(2):68-73.
Jehangir S, Nanjundaiah P, Sigamani E, et al. Pathological prognostication of paediatric adrenocortical tumours: is a gold standard emerging. Pediatr Blood Cancer. 2019;66:e27567.
Kerkhofs TM, Ettaieb MH, Verhoeven RH, et al. Adrenocortical carcinoma in children: first population-based clinicopathological study with long-term follow-up. Oncol Rep. 2014;32(6):2836-2844.
Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab. 2001;86(10):4970-4973.
Loncarevic IF, Hering A, Posorski N, Linden T, Hoyer H, Bucky P. Number of genomic imbalances correlates with the overall survival for adrenocortical cancer in childhood. Pediatr Blood Cancer. 2008;51:356-362.
Lorea CF, Moreno DA, Borges KS, et al. Expression profile of apoptosis-related genes in childhood adrenocortical tumors: low level of expression of BCL2 and TNF genes suggests a poor prognosis. Eur J Endocrinol. 2012;167(2):199-208.
Mayer SK, Oligny LL, Deal C, Yazbeck S, Gagné N, Blanchard H. Childhood adrenocortical tumors: case series and reevaluation of prognosis-a 24-year experience. J Pediatr Surg. 1997;32(6):911-915.
McDonnell CM, Zacharin MR. Adrenal cortical tumours: 25 years’ experience at the Royal Children's Hospital, Melbourne. J Paediatr Child Health. 2003;39:682-685.
Mendonca BB, Lucon AM, Menezes CA, et al. Clinical, hormonal and pathological findings in a comparative study of adrenocortical neoplasms in childhood and adulthood. J Urol. 1995;154(6):2004-2009.
Mishra A, Agarwal G, Misra AK, Agarwal A, Mishra SK. Functioning adrenal tumours in children and adolescents: an institutional experience. ANZ J Surg. 2001;71:103-107.
Monteiro NML, Rodrigues KES, Vidigal PVT, Oliveira BM. Adrenal carcinoma in children: longitudinal study in Minas Gerais, Brazil. Rev Paul Pediatr. 2019;37(1):20-26.
Narasimhan KL, Samujh R, Bhansali A, et al. Adrenocortical tumors in childhood. Pediatr Surg Int. 2003;19:432-435.
Parise IZS, Parise GA, Noronha L, et al. The prognostic role of CD8(+) T lymphocytes in childhood adrenocortical carcinomas compared to Ki-67, PD-1, PD-L1, and the Weiss score. Cancers (Basel). 2019;11(11):1730.
Pinto EM, Billerbeck AEC, Villares Fragoso MCB, Mendonca B, Latronico AC. J Clin Endocrinol Metab. 2005;90(5):2976-2981.
Pinto EM, Rodriguez-Galindo C, Pounds SB, et al. Identification of clinical and biologic correlates associated with outcome in children with adrenocortical tumors without germline TP53 mutations: a St Jude Adrenocortical Tumor Registry and Children's Oncology Group study. J Clin Oncol. 2017;35(35):3956-3963.
Rosati R, Cerrato F, Doghman M, et al. High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tutors positive for the R337H TP53 mutation. Cancer Genet Cytogenet. 2008;186:19-24.
Sakoda A, Mushtaq I, Levitt G, Sebire NJ. Clinical and histopathological features of adrenocortical neoplasms in children: retrospective review from a single specialist center. J Pediatr Surg. 2014;49(3):410-415.
Sandrini F, Villani DP, Tucci S, Moreira AC, de Castro M, Elias LL. Inheritance of R337H p53 gene mutation in children with sporadic adrenocortical tumor. Horm Metab Res. 2005;37(4):231-235.
Wendt S, Shelso J, Wright K, Furman W. Neoplastic causes of abnormal puberty. Pediatr Blood Cancer. 2014;61:664-671.
Wilkin F, Gagné N, Paquette J, Oligny LL, Cheri D. Pediatric adrenocortical tumors: molecular events leading to insulin-like growth factor II gene overexpression. J Clin Endocrinol Metab. 2000;85(5):2048-2056.
Zekri W, Hammad M, Rashed WM, et al. The outcome of childhood adrenocortical carcinoma in Egypt: a model from developing countries. Pediatr Hematol Oncol. 2020;37(3):198-210.
Bulzico D, de Faria PA, de Paula MP, et al. Recurrence and mortality prognostic factors in childhood adrenocortical tumors: analysis from the Brazilian National Institute of Cancer experience. Pediatr Hematol Oncol. 2016;33(4):248-258.
Misu Y, Jiang S, Yukfumi Y, et al. Clinicopathological features of pediatric functional adrenocortical carcinoma diagnosed by Weiss criteria; an analysis of four cases. Clin Pediatr Endocrinol. 2001;10(2):141-146.
Pinto EM, Faucz FR, Paza LZ, et al. Germline variants in phosphodiesterase genes and genetic predisposition to pediatric adrenocortical tumors. Cancers (Basel). 2020;12(2):506.
Waldmann J, Patsalis N, Fendrich V, et al. Clinical impact of TP53 alterations in adrenocortical carcinomas. Langenbecks Arch Surg. 2012;397(2):209-216.
Ciftci AO, Senocak ME, Tanyel FC, Büyükpamukçu N. Adrenocortical tumors in children. J Pediatr Surg. 2001;36(4):549-554.
Wolthers OD, Cameron FJ, Scheimberg I, et al. Androgen secreting adrenocortical tumours. Arch Dis Child. 1999;80(1):46-50.
Driver CP, Birch J, Gough DC, Bruce J. Adrenal cortical tumors in childhood. Pediatr Hematol Oncol. 1998;15(6):527-532.
Teinturier C, Pauchard MS, Brugières L, Landais P, Chaussain JL, Bougnères PF. Clinical and prognostic aspects of adrenocortical neoplasms in childhood. Med Pediatr Oncol. 1999;32(2):106-111.
McAteer JP, Huaco JA, Gow KW. Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study. J Pediatr Surg. 2013;48(5):1025-1031.
Picard C, Faure-Conter C, Leblond P, et al. Exploring heterogeneity of adrenal cortical tumors in children: the French pediatric rare tumor group (Fracture) experience. Pediatr Blood Cancer. 2020;67:e28086.
Redlich A, Boxberger N, Strugala D, et al. Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial. Klin Padiatr. 2012;224:366-371.
Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189-2197.
Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372-2380.
Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012;152(6):1150-1157.
Hubertus J, Boxberger N, Redlich A, von Schweinitz D, Vorwerk P. Surgical aspects in the treatment of adrenocortical carcinomas in children: data of the GPOH-MET 97 trial. Klin Padiatr. 2012;224:143-147.
Miller BS. Changes in the evaluation and management of adrenocortical carcinoma. Ann Surg Oncol. 2018;25(12):3413-3415.